A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001

Bryan Oronsky, Scott Caroen, Karen Zeman, Mary Quinn, Christina Brzezniak, Jan Scicinski, Pedro Cabrales, Tony R. Reid, Jane B. Trepel, Nacer D. Abrouk, Christopher Larson, Arnold Oronsky, Harry E. Lybeck, Regina M. Day, Corey A. Carter

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevi-tably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensi-tive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, the patient maintained a good quality of life and performance status.

Original languageEnglish (US)
Pages (from-to)105-108
Number of pages4
JournalClinical Medicine Insights: Oncology
StatePublished - Nov 6 2016


  • Epigenetic
  • Platinum doublets
  • RRx-001
  • Resensitization
  • Resistance reversal
  • Resistant SCLC

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001'. Together they form a unique fingerprint.

Cite this